您好,欢迎访问仪器信息网
注册
上海基免实业有限公司

关注

已关注

已认证

粉丝量 0

当前位置: 上海基免 > 抗体/抗原 > 磷酸化细丝蛋白A抗体,Anti-phospho-Filamin A/FLNA (Ser2522)

磷酸化细丝蛋白A抗体,Anti-phospho-Filamin A/FLNA (Ser2522)

供货周期: 一周
品牌:
规格: 0.2ml/200μg
货号:
CAS号:
报价: ¥1
留言咨询
产品介绍
磷酸化细丝蛋白A抗体英文名称  Anti-phospho-Filamin A/FLNA (Ser2522) 
中文名称  磷酸化细丝蛋白A抗体 
别    名  ABP 280; ABP 280 like protein; ABP-280; ABP280A; ABPA antibody Actin binding like protein; Actin binding protein 280; Actin-binding protein 280; Alpha filamin; Alpha-filamin; APBX; cb967; Dilp2; Endothelial actin binding protein; Endothelial actin-binding protein; Filamin 1; Filamin A alpha actin binding protein 280; Filamin A; Filamin-1; Filamin-A; FLN; FLN-A; FLN1; FLNA; FLNA_HUMAN; FMD; MNS; NHBP; Non muscle filamin; Non-muscle filamin; OPD; OPD1; OPD2. 
浓    度  1mg/1ml 
规 格  0.1ml/100μg     
纯化的抗体可通过不同的途径获取,有些磷酸化细丝蛋白A抗体可通过下述方法制备或从商家购买。从商家购买的抗体,通常附有正确的储存方法。
1)工作液应在4℃下融化并存放,可能稳定达数月。
2)如果没有特殊原因而避免使用叠氮钠,亦可加入叠氮钠,浓度为0.02%。将纯化的抗体样本分装成合适的体积,于-20℃保存。
3)纯化的抗体溶液应以较高的浓度(如lmg/m1)在中性pH下保存。:常用的抗体储存浓度高达l0mg/ml。较低浓度的抗体冻存前应浓缩。所有标准的浓缩方法(如超滤法),皆可使用。还有一个简单的方法是用蛋白A或蛋白G亲和柱来浓缩溶液。如果纯化的抗体不是用于标记,可将它们以较低浓度储存于加有1%BSA的溶液中。
4)经纯化制备的抗体在常用的缓冲液中是稳定的。其DH应保持在中性左右。如果pH在7-8之间,即使保存多年,对抗体也无损害。多数情况下,盐浓度适于保持在0-150mmol/L之间,但在长期存放的抗体中,盐溶液浓度高达500mmol/L时,对磷酸化细丝蛋白A抗体可能有损害。如果没有其他说明.律议用PBS或50mmol/LTris(DH8.0)溶液长期存放抗体。  
抗体来源  Rabbit  
克隆类型  polyclonal 
交叉反应  Human, Mouse, Rat, Dog, Horse
产品类型  一抗  磷酸化抗体   
研究领域  免疫学 神经生物学 通道蛋白 结合蛋白  
蛋白分子量  predicted molecular weight: 291kDa 
性    状  Lyophilized or Liquid 
免 疫 原  KLH conjugated Synthesised phosphopeptide derived from human FLNA around the phosphorylation site of Ser2522 
亚    型  IgG 
纯化方法  affinity purified by Protein A 
储 存 液  0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide 
产品应用   ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500 
(石蜡切片需做抗原修复) 
 not yet tested in other applications.
 optimal dilutions/concentrations should be determined by the end user.  
保存条件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 
Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 
磷酸化细丝蛋白A抗体产品介绍 Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNA may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking.
Function : Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNA may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking. Involved in ciliogenesis.
Subunit : Interacts with PDLIM2 (By similarity). Homodimer. Interacts with FCGR1A, FLNB, FURIN, HSPB7, INPPL1, KCND2, MYOT, MYOZ1, ARHGAP24, PSEN1, PSEN2 and ECSCR. Interacts also with various other binding partners in addition to filamentous actin. Interacts (via N-terminus) with MIS18BP1 (via N-terminus). Interacts (via N-terminus) with TAF1B. Interacts with TMEM67 (via C-terminus) and MKS1.
Subcellular Location : Cytoplasm, cell cortex. Cytoplasm, cytoskeleton.
Tissue Specificity : Ubiquitous.
Post-translational modifications : Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylation extent changes in response to cell activation.
DISEASE : Defects in FLNA are the cause of periventricular nodular heterotopia type 1 (PVNH1) [MIM:300049]; also called nodular heterotopia, bilateral periventricular (NHBP or BPNH). PVNH is a developmental disorder characterized by the presence of periventricular nodules of cerebral gray matter, resulting from a failure of neurons to migrate normally from the lateral ventricular proliferative zone, where they are formed, to the cerebral cortex. PVNH1 is an X-linked dominant form. Heterozygous females have normal intelligence but suffer from seizures and various manifestations outside the central nervous system, especially related to the vascular system. Hemizygous affected males die in the prenatal or perinatal period. 
Defects in FLNA are the cause of periventricular nodular heterotopia type 4 (PVNH4) [MIM:300537]; also known as periventricular heterotopia Ehlers-Danlos variant. PVNH4 is characterized by nodular brain heterotopia, joint hypermobility and development of aortic dilation in early adulthood. 
Defects in FLNA are the cause of otopalatodigital syndrome type 1 (OPD1) [MIM:311300]. OPD1 is an X-linked dominant multiple congenital anomalies disease mainly characterized by a generalized skeletal dysplasia, mild mental retardation, hearing loss, cleft palate, and typical facial anomalies. OPD1 belongs to a group of X-linked skeletal dysplasias known as oto-palato-digital syndrome spectrum disorders that also include OPD2, Melnick-Needles syndrome (MNS), and frontometaphyseal dysplasia (FMD). Remodeling of the cytoskeleton is central to the modulation of cell shape and migration. FLNA is a widely expressed protein that regulates re-organization of the actin cytoskeleton by interacting with integrins, transmembrane receptor complexes and second messengers. Males with OPD1 have cleft palate, malformations of the ossicles causing deafness and milder bone and limb defects than those associated with OPD2. Obligate female carriers of mutations causing both OPD1 and OPD2 have variable (often milder) expression of a similar phenotypic spectrum. 
Defects in FLNA are the cause of otopalatodigital syndrome type 2 (OPD2) [MIM:304120]; also known as cranioorodigital syndrome. OPD2 is a congenital bone disorder that is characterized by abnormally modeled, bowed bones, small or absent first digits and, more variably, cleft palate, posterior fossa brain anomalies, omphalocele and cardiac defects. 
Defects in FLNA are the cause of frontometaphyseal dysplasia (FMD) [MIM:305620]. FMD is a congenital bone disease characterized by supraorbital hyperostosis, deafness and digital anomalies. 
Defects in FLNA are the cause of Melnick-Needles syndrome (MNS) [MIM:309350]. MNS is a severe congenital bone disorder characterized by typical facies (exophthalmos, full cheeks, micrognathia and malalignment of teeth), flaring of the metaphyses of long bones, s-like curvature of bones of legs, irregular constrictions in the ribs, and sclerosis of base of skull. 
Defects in FLNA are the cause of X-linked congenital idiopathic intestinal pseudoobstruction (CIIPX) [MIM:300048]. CIIPX is characterized by a severe abnormality of gastrointestinal motility due to primary qualitative defects of enteric ganglia and nerve fibers. Affected individuals manifest recurrent signs of intestinal obstruction in the absence of any mechanical lesion. 
Defects in FLNA are the cause of FG syndrome type 2 (FGS2) [MIM:300321]. FG syndrome (FGS) is an X-linked disorder characterized by mental retardation, relative macrocephaly, hypotonia and constipation. 
Defects in FLNA are the cause of terminal osseous dysplasia (TOD) [MIM:300244]. A rare X-linked dominant male-lethal disease characterized by skeletal dysplasia of the limbs, pigmentary defects of the skin and recurrent digital fibroma during infancy. A significant phenotypic variability is observed in affected females. 
Defects in FLNA are the cause of cardiac valvular dysplasia X-linked (CVDX) [MIM:314400]. A rare X-linked heart disease characterized by mitral and/or aortic valve regurgitation. The histologic features include fragmentation of collagenous bundles within the valve fibrosa and accumulation of proteoglycans, which produces excessive valve tissue leading to billowing of the valve leaflets. 
Note=Defects in FLNA may be a cause of macrothrombocytopenia, a disorder characterized by subnormal levels of blood platelets. Blood platelets are abonormally enlarged.
Similarity : Belongs to the filamin family.
Contains 1 actin-binding domain.
Contains 2 CH (calponin-homology) domains.
Contains 24 filamin repeats.
Database links : UniProtKB/Swiss-Prot: P21333.4
内皮细胞肌动蛋白结合蛋白(肌动结合蛋白样蛋白)
 

工商信息

企业名称

上海基免实业有限公司

企业信息已认证

企业类型

信用代码

310116002801941

成立日期

2013-03-11

注册资本

10

经营范围

联系方式
磷酸化细丝蛋白A抗体,Anti-phospho-Filamin A/FLNA (Ser2522)由上海基免实业有限公司为您提供,货号,规格:0.2ml/200μg ,CAS号:,如您想了解更多关于磷酸化细丝蛋白A抗体,Anti-phospho-Filamin A/FLNA (Ser2522)价格、磷酸化细丝蛋白A抗体,Anti-phospho-Filamin A/FLNA (Ser2522)结构式、批发、用途等信息,欢迎咨询。除供应磷酸化细丝蛋白A抗体,Anti-phospho-Filamin A/FLNA (Ser2522)外,还可为您提供黄曲霉毒素(AF)检测试剂盒、安普霉素(Apramycin)检测试剂盒、大豆凝集素(SBA)检测试剂盒等试剂,公司有专业的客户服务团队,是您值得信赖的合作伙伴,上海基免客户服务电话,售前、售后均可联系。
推荐产品
供应产品

上海基免实业有限公司

沟通底价

提交后,商家将派代表为您专人服务

获取验证码

{{maxedution}}s后重新发送

获取多家报价,选型效率提升30%
提交留言
点击提交代表您同意 《用户服务协议》 《隐私政策》 且同意关注厂商展位
联系方式:

公司名称: 上海基免实业有限公司

公司地址: 上海市金山工业区亭卫公路6558号9幢2441室 联系人: 肖菊芳 邮编: 201507

主营产品:

仪器信息网APP

展位手机站